Skip to main content

Response to “COVID-19: room for treating T cell exhaustion?”

The Original Article was published on 15 May 2020

Dear Editor,

Riva et al. elegantly discuss the complex balance between immunosuppressive and immunostimulating factors in the treatment of COVID-19 and raise the point that therapeutic approaches to enhance immune function, particularly T cell functions, have not yet been attempted in this setting [1]. Recent data describing circulating SARS-CoV-2-specific CD8+ and CD4+ T cells in COVID-19 convalescent patients further support the potential utility of enhancing T cell activity [2].

One additional factor to consider is the influence of patient temperature on immune function. Several studies show that elevated temperature boosts multiple aspects of both humoral and cellular immunity, including antibody production, T cell activation, and macrophage function. Fever promotes T lymphocyte trafficking through heat shock protein 90 (Hsp90)-induced α4 integrin activation and signaling in T cells, promoting T cell adhesion and migration to enhance immune surveillance during infection [3]. A retrospective review of over 400 patients with sepsis suggests that moderate fever (38.3–39.4 °C) is protective [4]. Prospective data have shown that afebrile patients have higher 28-day mortality (37.5% vs 18.2%), increased acquisition of secondary infections (35.4% vs. 15.9%), and suppressed HLA-DR expression over time (a finding suggestive of monocyte dysfunction in sepsis) [5]. A pilot randomized controlled study of external warming of septic patients ( identifier: NCT02706275) has recently completed enrollment.

The importance of patient temperature, and the potential for benefits from warming in a variety of infectious conditions, including COVID-19, warrants continued study. A recently posted randomized controlled trial protocol is a further step towards this goal (

Authors’ response

Giovanni Riva, Vincenzo Nasillo, Enrico Tagliafico, Tommaso Trenti, Mario Luppi

Dear Editor,

We read with interest the comment by Drewry and colleagues, pointing out the relevant effects of patient temperature on immune function. In particular, the authors remark the potential improvement of pathogen-specific T cell responses and innate immunity associated with 1–2° increase of body temperature (i.e., moderate fever), which appeared to be correlated with a better outcome in critically ill infected patients, suggesting that external “core warming” may represent a valuable non-pharmaceutical intervention to enhance anti-pathogen immunity in septic patients, including those with COVID-19.

In line with this observation, it has recently been highlighted that climatic environmental factors (such as low temperatures and dry air) directly influence clinico-epidemiological manifestations of respiratory virus infections (included coronaviruses), showing typical outbreaks in the cold season, while vanishing or just causing mild symptoms in the summer months. Indeed, cold climate may promote intrinsic virulence of these air borne pathogens, but may also modulate host antiviral immunity, causing a pivotal reduction of both adaptive and innate immune functions [6]. By considering this, early warming approaches could be beneficial in patients with moderate COVID-19, in order to prevent progression to severe disease. However, it has been noticed that also hot ambient temperatures may weaken antiviral T cell responses [6], and this could be reminiscent of what happens in virus-associated hyper-inflammatory syndromes, namely secondary hemophagocytic lymphohistiocytosis (sHLH) and macrophage activation syndrome (MAS), characterized by cytokine storms, unremitting high fever, and impaired virus control by specific T lymphocytes. In turn, following the “Goldilocks principle”—neither too cold, neither too hot—already well recognized in a variety of natural and biological phenomena, active temperature management may provide the right range of body temperature to maximize specific antimicrobial functions of the immune system, in particular, against pathogens inducing sepsis-like dysfunctional immunity.

Availability of data and materials



  1. Riva G, Nasillo V, Tagliafico E, Trenti T, Luppi M. COVID-19: room for treating T cell exhaustion? Crit Care. 2020;24(1):229.

    Article  Google Scholar 

  2. Grifoni A, Weiskopf D, Ramirez SI, Mateus J, Dan JM, Moderbacher CR, Rawlings SA, Sutherland A, Premkumar L, Jadi RS, et al. Targets of T cell responses to SARS-CoV-2 coronavirus in humans with COVID-19 disease and unexposed individuals. Cell. In Press.

  3. Lin C, Zhang Y, Zhang K, Zheng Y, Lu L, Chang H, Yang H, Yang Y, Wan Y, Wang S, et al. Fever promotes T lymphocyte trafficking via a thermal sensory pathway involving heat shock protein 90 and alpha4 integrins. Immunity. 2019;50(1):137–51 e136.

    Article  CAS  Google Scholar 

  4. Evans EM, Doctor RJ, Gage BF, Hotchkiss RS, Fuller BM, Drewry AM. The association of fever and antipyretic medication with outcomes in mechanically ventilated patients: a cohort study. Shock. 2019;52(2):152–9.

    Article  Google Scholar 

  5. Drewry AM, Ablordeppey EA, Murray ET, Dalton CM, Fuller BM, Kollef MH, Hotchkiss RS. Monocyte function and clinical outcomes in febrile and afebrile patients with severe sepsis. Shock. 2018;50(4):381–7.

    Article  Google Scholar 

  6. Moriyama M, Hugentobler WJ, Iwasaki A. Seasonality of respiratory viral infections. Annu Rev Virol. 2020. doi: Online ahead of print PMID: 32196426.

Download references





Author information

Authors and Affiliations



Conception and writing: A.D., R.H., and E.K. Critical revision: A.D. and R.H. Final approval: A.D., R.H., and E.K. The authors read and approved the final manuscript.

Corresponding author

Correspondence to Erik Kulstad.

Ethics declarations

Ethics approval and consent to participate


Consent for publication


Competing interests

A.D. was supported by the National Institutes for Health grant K23GM129660.

R.H. has received no direct financial support, nor does he or his family hold patents or equity interest in any biotech or pharmaceutical company. He has received laboratory research support from the Bristol-Myers Squibb, GlaxoSmithKline, and RevImmune; has served as a paid consultant to the Bristol-Myers Squibb and GlaxoSmithKline; and has received grant support from the US NIH and US Public Health Service for research investigations of sepsis.

E.K. has an equity interest in Attune Medical.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Drewry, A.M., Hotchkiss, R. & Kulstad, E. Response to “COVID-19: room for treating T cell exhaustion?”. Crit Care 24, 345 (2020).

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: